| Authors: |
Muik A; BioNTech SE, Mainz, Germany., Altintas I; Genmab, Utrecht, The Netherlands., Gieseke F; BioNTech SE, Mainz, Germany., Schoedel KB; BioNTech SE, Mainz, Germany., Burm SM; Genmab, Utrecht, The Netherlands., Toker A; BioNTech SE, Mainz, Germany., Salcedo TW; Genmab, Princeton, NJ, USA., Verzijl D; BioNTech SE, Mainz, Germany.; Genmab, Utrecht, The Netherlands.; Genmab, Princeton, NJ, USA.; TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany., Eisel D; BioNTech SE, Mainz, Germany., Grunwitz C; BioNTech SE, Mainz, Germany., Kranz LM; BioNTech SE, Mainz, Germany., Vormehr M; BioNTech SE, Mainz, Germany., Satijn DPE; BioNTech SE, Mainz, Germany.; Genmab, Utrecht, The Netherlands.; Genmab, Princeton, NJ, USA.; TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany., Diken M; BioNTech SE, Mainz, Germany., Kreiter S; BioNTech SE, Mainz, Germany., Sasser K; Genmab, Princeton, NJ, USA., Ahmadi T; BioNTech SE, Mainz, Germany.; Genmab, Utrecht, The Netherlands.; Genmab, Princeton, NJ, USA.; TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany., Türeci Ö; BioNTech SE, Mainz, Germany., Breij ECW; Genmab, Utrecht, The Netherlands., Jure-Kunkel M; Genmab, Princeton, NJ, USA., Sahin U; BioNTech SE, Mainz, Germany.; TRON - Translational Oncology at the University Medical Center of the Johannes Gutenberg University gGmbH, Mainz, Germany. |
